USFDA ESG NextGen Update: FAERS Submission Type Removal
The U.S. Food and Drug Administration (FDA) is developing its regulatory submission systems under the Electronic Submission Gateway NextGen (ESG NextGen) system. There was a significant change that has been made regarding the FDA Adverse Event Reporting System (FAERS) recently. Some forms of submissions to FAERS have been eliminated and cease to be effective without delay.
This is a major revolution in the life sciences organizations, pharmaceutical firms and regulatory teams that have relied on such types of submissions to report adverse events. It is essential to make sure that these updates are adhered to, which will guarantee that the regulations are aligned and that there can be no mistakes in submissions.
Removed FAERS Submission Types
The following table highlights the submission types that have been removed from ESG NextGen:
Center Submission Type
CBER AERS_ATTACHMENTS_PREMKT_CBER
CDER AERS IND
CDER AERS Attachments IND
CDER AERS_Attachments_PREMKT
CDER AERS_ATTACHMENTS_PREMKT_CDER
CDER AERS_PREMKT
Organizations currently using any of these submission types should immediately review their submission workflows. Using deprecated submission types may result in processing errors or delays in FDA review.
Next Steps for Organizations
In case any of the removed types of submissions is needed by your organization it is highly essential to shift to the relevant alternative as soon as possible. The FDA advises to address FAERSESUB@fda.hhs.gov concerning the appropriate type of submission to be used in the future.
This revision is in line with the continued action by the FDA to simplify the submission procedures and make the reporting of adverse events more efficient and compliant. With submission methods that are actively updated, your organization is able to keep operating as required without any interference.
How Masuu Global Can Help
"Masuu Global" assists life sciences organizations in overcoming regulatory change such as the ESG NextGen updates. Our team will assist in making sure that there is a seamless transition, assist you in adjusting your processes, and reduce the risks of non-compliance.
The necessity to keep up and remain responsive to FDA changes in order to remain efficient in operations and regulatory compliance. Contact our team to make sure that your FAERS filings are all updated with the current ESG NextGen provisions.
Related Links:
MasuuGlobal
###
Sponsor Message
For millions of Americans, Canadian pharmacies provide an affordable solution for essential prescriptions such as Lipitor and Crestor to manage cholesterol, or Nexium for GERD and acid reflux. Patients with chronic illnesses often use insulin therapies like Humalog and Lantus for diabetes and respiratory treatments like Advair Diskus and Ventolin inhalers. Managing depression, anxiety, or bipolar disorder is possible with medications like Zoloft, Prozac, and Abilify, while blood thinners such as Eliquis, Plavix, and Xarelto provide heart health benefits. Popular therapies for pain management, such as Celebrex, and for thyroid health, like Synthroid, are frequently ordered. In addition, medications such as Viagra and Cialis are commonly used to treat erectile dysfunction, while Januvia aids in managing Type 2 diabetes. Wakefulness-promoting agents such as Provigil and Nuvigil are crucial for those combating narcolepsy or chronic sleepiness. With options like Cymbalta for nerve pain and Aricept for Alzheimer's, Canadian pharmacies provide access to a wide range of affordable, life-enhancing medications for patients across the United States.
